These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Rationale for the use of alendronate in osteoporosis. Kanis JA; Gertz BJ; Singer F; Ortolani S Osteoporos Int; 1995 Jan; 5(1):1-13. PubMed ID: 7703618 [TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates: preclinical aspects and use in osteoporosis. Fleisch HA Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324 [TBL] [Abstract][Full Text] [Related]
5. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Plosker GL; Goa KL Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833 [TBL] [Abstract][Full Text] [Related]
6. New bisphosphonates in osteoporosis. Fleisch H Osteoporos Int; 1993; 3 Suppl 2():S15-22. PubMed ID: 8481594 [TBL] [Abstract][Full Text] [Related]
7. Clinical trials with bisphosphonates. Lombardi A; Santora AC Ann Ital Med Int; 1992; 7(3 Suppl):158S-165S. PubMed ID: 1297394 [TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates in the treatment of disorders of mineral metabolism. Singer FR; Minoofar PN Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099 [TBL] [Abstract][Full Text] [Related]
10. Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis. McClung MR Bone; 1996 Nov; 19(5 Suppl):195S-198S. PubMed ID: 8922662 [TBL] [Abstract][Full Text] [Related]
11. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate. Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463 [TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates in prostate carcinoma. Adami S Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435 [TBL] [Abstract][Full Text] [Related]
13. Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates. Muratore M; Quarta E; Grimaldi A; Calcagnile F; Quarta L Drug Des Devel Ther; 2011; 5():445-54. PubMed ID: 22087064 [TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Morabito N; Lasco A; Gaudio A; Crisafulli A; Di Pietro C; Meo A; Frisina N Osteoporos Int; 2002 Aug; 13(8):644-9. PubMed ID: 12181623 [TBL] [Abstract][Full Text] [Related]
15. Clinical effects of bisphosphonates in involutional osteoporosis. Ott SM J Bone Miner Res; 1993 Dec; 8 Suppl 2():S597-606. PubMed ID: 8122531 [TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate therapy. Licata AA Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162 [TBL] [Abstract][Full Text] [Related]
17. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Fitton A; McTavish D Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854 [TBL] [Abstract][Full Text] [Related]
18. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526 [TBL] [Abstract][Full Text] [Related]
19. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484 [TBL] [Abstract][Full Text] [Related]
20. The role of bisphosphonates in the prevention and treatment of osteoporosis. Papapoulos SE Am J Med; 1993 Nov; 95(5A):48S-52S. PubMed ID: 8256796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]